This technology explores the feasibility of MCMs as tumor targets and their targeted small-molecule drugs from four perspectives: cellular level, clinical tissue samples, animal experiments, and drug development. It elucidates the molecular mechanism of inhibiting MCMs to kill tumor cells and screens PROTAC small-molecule drugs based on this target.

Technology provider:Xi'an Jiaotong University